[Form 4] MetLife, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MetLife, Inc. (NYSE: MET) – Form 4 insider transaction filed 20 Jun 2025

Non-management director Diana McKenzie reported the acquisition of 562 shares of MetLife common stock on 17 Jun 2025 at a reference price of $77.85 per share. The transaction was coded “A(1),” indicating the shares were issued as part of the company’s non-management director compensation plan rather than an open-market purchase. After the grant, McKenzie’s direct beneficial ownership rose to 22,065 shares.

The filing notes that the director elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors. No derivative securities were reported, and there were no dispositions.

While the amount is immaterial relative to MetLife’s ~805 million shares outstanding, routine equity compensation aligns director incentives with shareholder returns and remains a data point for governance and insider-sentiment trackers.

Positive

• Director’s beneficial ownership increased, marginally strengthening board-shareholder alignment.

Negative

• Shares were granted as routine compensation rather than purchased with personal funds, limiting any positive signaling effect.

Insights

Securities Analyst

TL;DR: Routine director stock grant; immaterial size; neutral impact on MET valuation.

The filing reflects a regularly scheduled equity retainer paid in stock, deferred under the company’s director comp plan. The 562-share grant is worth roughly $44k, negligible versus MetLife’s $58 bn market cap and does not signal incremental insider conviction because no cash was deployed. It modestly increases alignment but has no bearing on earnings, capital, or strategy. I classify the market impact as neutral; tracker services will log the purchase, yet trading volumes or sentiment should remain unaffected.

Corporate Governance Expert

TL;DR: Demonstrates equity-based director pay; strengthens alignment but routine, not market-moving.

MetLife continues to compensate independent directors partly in common stock, a governance best practice that ties oversight incentives to shareholder value. The deferral underscores long-term orientation. However, because the grant is formulaic and represents less than 0.0001% of outstanding shares, it carries no governance red flags or positive surprises. Investors should view the filing as standard disclosure, with no expectation of strategic shift or insider information.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCKENZIE DIANA

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		A(1)		562	A	$77.85	22,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Remarks:

	/s/ Morgan Mayes, Authorized Signer	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MetLife (MET) shares did Director Diana McKenzie acquire?

562 shares were acquired on 17 Jun 2025.

What was the acquisition price reported in the Form 4?

The reported price was $77.85 per share.

Did the director buy the shares on the open market?

No. The shares were issued as part of non-management director compensation and deferred under MetLife’s plan.

What is Diana McKenzie’s total direct ownership after the transaction?

She now directly beneficially owns 22,065 MET shares.

Does the Form 4 indicate any derivative securities or dispositions?

No. No derivatives or share sales were reported.